Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vaccinex Inc (NQ: VCNX ) 3.220 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vaccinex Inc < Previous 1 2 3 4 5 6 Next > Stocks That Hit 52-Week Lows On Wednesday April 26, 2023 On Wednesday, 345 companies set new 52-week lows. Via Benzinga Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab April 25, 2023 From Vaccinex, Inc. Via GlobeNewswire Why Is Vaccinex (VCNX) Stock Up 67% Today? February 07, 2023 Vaccinex (VCNX) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. Via InvestorPlace Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells April 12, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Announces Private Placement with Commitments of $5.0 Million April 03, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs April 03, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference March 23, 2023 March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease From Vaccinex, Inc. Via GlobeNewswire Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) March 21, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis March 09, 2023 From Vaccinex, Inc. Via GlobeNewswire Stocks That Hit 52-Week Lows On Tuesday March 21, 2023 On Tuesday, 74 companies achieved new lows for the year. Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session March 03, 2023 Via Benzinga Stocks That Hit 52-Week Lows On Thursday March 16, 2023 Thursday's session saw 337 companies set new 52-week lows. Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session February 17, 2023 Via Benzinga MarketBeat Week in Review – 2/6 - 2/10 February 11, 2023 Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely Via MarketBeat Topics Artificial Intelligence Economy Exposures Artificial Intelligence Economy Interest Rates 12 Health Care Stocks Moving In Wednesday's Pre-Market Session February 08, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday February 08, 2023 Our coverage starts today with a look at the biggest pre-market stock movers traders will want to keep an eye on Wednesday! Via InvestorPlace Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket February 08, 2023 Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement. Via Benzinga Should Investors Buy or Sell the Vaccinex Patent News? February 07, 2023 Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news? Via MarketBeat Topics Intellectual Property Exposures Intellectual Property Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today? February 07, 2023 Rubius Therapeutics (RUBY) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice. Via InvestorPlace Why Is Bed Bath & Beyond (BBBY) Stock Down 32% Today? February 07, 2023 Bed Bath & Beyond (BBBY) stock is falling on Tuesday after the retailer revealed plans to raise $1 billion and warned of investing risks. Via InvestorPlace Why Is Oak Street Health (OSH) Stock Up 36% Today? February 07, 2023 Oak Street Health (OSH) stock is on the rise Tuesday as investors react to a report that CVS (CVS) plans to take over the company. Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 07, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday February 07, 2023 It's time to start the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday! Via InvestorPlace The 3 Best Biotech Stocks Under $1 to Buy for January January 26, 2023 Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. Via InvestorPlace Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology January 09, 2023 Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform From Vaccinex, Inc. Via GlobeNewswire Vaccinex Announces $3.8 Million Private Placement November 28, 2022 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update November 14, 2022 Continued Progress in Pepinemab Oncology and Neurology Clinical Programs From Vaccinex, Inc. Via GlobeNewswire Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer November 10, 2022 New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment Options From Vaccinex, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session October 27, 2022 Gainers Clearside Biomedical (NASDAQ:CLSD) stock rose 27.3% to $1.35 during Thursday's pre-market session. The market value of their outstanding shares is at $81.2 million. Via Benzinga Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday October 26, 2022 Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company. Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
